Mustang Bio, Inc. (MBIO)
Nasdaq · Healthcare · Biotechnology
$0.4601−2.33%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.5M
- 52-week range
- $0.458 – $1.85
- 52-week change
- −73.09%
- EPS (trailing)
- −$0.44
Fiscal year to Dec 2025
- Net income
- −$1.9M
- Diluted EPS
- −$0.39
From the company’s annual report on SEC EDGAR.
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 4 employees · mustangbio.com